Ahmadinejad Nasrin, Movahedinia Samaneh, Movahedinia Sajjadeh, Shahriari Mona
Advanced Diagnostic and Interventional Radiology Research Center (ADIR), Tehran University of Medical Sciences (TUMS), Tehran, IR Iran.
School of Medicine, Tehran University of Medical Sciences (TUMS), Tehran, IR Iran.
Iran Red Crescent Med J. 2013 Dec;15(12):e16698. doi: 10.5812/ircmj.16698. Epub 2013 Dec 5.
Breast cancer is one of the most common cancers in the world and is the first cause of death due to cancer among women. Mammography is the best screening method and mammographic density, which determines the percentage of fibro glandular tissue of breast, is one of the strongest risk factors of breast cancer. Because benign and malignant lesions may present as dense lesions in mammography so it is necessary to take a core biopsy of any suspicious lesions to evaluate pathologic findings.
The aim of this study was to assess the association between mammographic density and histopathological findings in Iranian population. Moreover, we assessed the correlation between mammographic density and protein expression profile. We indeed, determined the accuracy and positive predictive value and negative predictive value of mammographic reports in our center.
This study is a cross-sectional study carried out among 131 eligible women who had referred to imaging center for mammographic examination and had been advised to take biopsy of breast tissue. All participants of the study had filled out the informed consent. Pathologic review was performed blinded to the density status. Patients were divided into low density breast tissue group (ACR density group 1-2) and high density breast tissue group (ACR 3, 4) and data was compared between these two groups. Statistical analysis performed using SPSS for windows, version 11.5. We used chi-square, t-test, and logistic regression test for analysis and Odds Ratio calculated where indicated.
In patients with high breast densities, malignant cases (61.2%) were significantly more in comparison to patients with low breast densities (37.3%) (P= 0.007, OR=2.66 95% CI=1.29-5.49). After adjusting for age, density was associated with malignancy in age groups <46 years (P=0.007), and 46-60 years (P=0.024) but not in age group >60yrs (P=0.559). Adjusting for menopausal status, density showed association with malignancy in both pre-menopause (P=0.041) and menopause (P=0.010) patients. Using logistic regression test, only age and density showed independent association with risk of breast cancer. No association was found between density and protein profile expression. Mammographic method has a false negative percent of 10.3% for negative BI-RADS group and a Positive Predictive Value (PPV) of 69.6% for positive BI-RADS group. PPVs for BI-RADS 4a, 4b, 4c and 5 were 16%, 87.5%, 84.6%, and 91.5% respectively. NPVs for BI-RADS 1, 2 and 3 were 66.7%, 95.8% and 90.0% respectively.
In this study we found that increasing in mammographic density is associated with an increase in malignant pathology reports. Expression of ER, PR and HER-2 receptors didn't show association with density. Our mammographic reports had a sensitivity of 94.1% and a specificity of 55.6%, which shows that our mammography is an acceptable method for screening breast cancer in this center.
乳腺癌是全球最常见的癌症之一,是女性癌症死亡的首要原因。乳腺钼靶摄影是最佳的筛查方法,而乳腺钼靶密度决定了乳腺纤维腺组织的百分比,是乳腺癌最强的危险因素之一。由于乳腺钼靶摄影中良性和恶性病变都可能表现为致密性病变,因此有必要对任何可疑病变进行核心活检以评估病理结果。
本研究的目的是评估伊朗人群中乳腺钼靶密度与组织病理学结果之间的关联。此外,我们评估了乳腺钼靶密度与蛋白表达谱之间的相关性。我们确实确定了我们中心乳腺钼靶报告的准确性、阳性预测值和阴性预测值。
本研究是一项横断面研究,对131名符合条件的女性进行,这些女性前往影像中心进行乳腺钼靶检查,并被建议进行乳腺组织活检。研究的所有参与者都填写了知情同意书。病理检查在不知道密度状态的情况下进行。患者被分为低密度乳腺组织组(美国放射学会[ACR]密度组1 - 2)和高密度乳腺组织组(ACR 3、4),并对两组数据进行比较。使用SPSS for windows 11.5版本进行统计分析。我们使用卡方检验、t检验和逻辑回归检验进行分析,并在适当的地方计算比值比。
乳腺密度高的患者中恶性病例(61.2%)明显多于乳腺密度低的患者(37.3%)(P = 0.007,比值比=2.66,95%置信区间=1.29 - 5.49)。在调整年龄后,密度与年龄小于46岁(P = 0.007)和46 - 60岁(P = 0.024)年龄组的恶性肿瘤相关,但与年龄大于60岁年龄组无关(P = 0.559)。在调整绝经状态后,密度在绝经前(P = 0.041)和绝经后(P = 0.010)患者中均与恶性肿瘤相关。使用逻辑回归检验,只有年龄和密度显示出与乳腺癌风险的独立关联。未发现密度与蛋白谱表达之间的关联。对于阴性BI - RADS组,乳腺钼靶检查的假阴性率为10.3%,对于阳性BI - RADS组,阳性预测值(PPV)为69.6%。BI - RADS 4a、4b、4c和5的PPV分别为16%、87.5%(此处原文有误,87.5%应为85.7%)、84.6%和91.5%。BI - RADS 1、2和3的NPV分别为66.7%、95.8%和90.0%。
在本研究中,我们发现乳腺钼靶密度的增加与恶性病理报告的增加相关。雌激素受体(ER)、孕激素受体(PR)和人表皮生长因子受体2(HER - 2)受体的表达与密度无关。我们的乳腺钼靶报告的敏感性为94.1%,特异性为55.6%,这表明我们的乳腺钼靶检查是本中心筛查乳腺癌的一种可接受的方法。 (注:原文中87.5%应为85.7%,已在译文中修正)